Dosing in the first phase of the phase 1/2 OCU410ST GARDian trial for Stargardt disease is complete. The European Medicines Agency (EMA) has granted orphan medicinal product designation for OCU410ST ...

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

Gupta is a nationally recognized retinal surgeon and an entrepreneur whose knowledge and experience on the phases of drug development and medical devices. Sunil Gupta, MD, has joined the Nanoscope ...

Study participants include people with no diabetes as well as those with various stages of the condition, creating a set of information distinct from previous research. Researchers have released the ...

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products.

A press release from the NIH announced that its scientific team has defined elements of brain-based visual impairment in children. Cerebral or cortical visual impairment (CVI) “has emerged as a ...

The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025. The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act ...

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development. Arctic Vision has signed a new commercial collaboration agreement with ...